The Food and Drug Administration (FDA) has been deliberating on the potential lifting of restrictions on four specific peptides. This decision comes after an all-day hearing where agency scientists argued against broadening access to unproven drugs that had been banned three years prior. [1]
In a more recent update, the FDA is also considering whether compounding pharmacies should be allowed to produce BPC-157 and TB-500, among other previously banned peptides. This decision would further expand the scope of peptide treatments available to patients. [2]
However, this process has not been without controversy. At a Correspondents’ Dinner event in July, former President Donald Trump's son-in-law, Ronny Jackson, who is also an FDA adviser, suggested that there had been "aggressive suppression" of peptides by the agency. He claimed that these treatments have potential benefits but were being unfairly restricted. [3]
Despite this suggestion from a high-profile figure, a panel of FDA advisers did vote to broaden access to certain peptides during their meeting on July 24th. This decision was seen as progress towards more patients having access to potentially beneficial peptide therapies. [1] The move has been met with mixed reactions, with some supporters arguing that the treatments could offer significant health benefits while others remain skeptical about their safety and efficacy.